Prevalence of the internalization-associated gene prtF1 in a bacterial population of Streptococcus pyogenes isolated from children with acute pharyngotonsillitis before and after antibiotic therapy.

The prevalence of the internalization-associated prtF1 gene was studied in 837 isolates of Streptococcus pyogenes obtained from 713 pediatric patients presenting with acute pharyngotonsillitis before and after antibiotic therapy. Its association with macrolide resistance and with bacteriological treatment failure was determined. The bacterial population isolated from baseline pharyngeal swabs showed an overall prtF1 positivity rate of 33%. A higher prtF1 positivity was found among erythromycin-resistant strains (45%) showing, however, marked differences between the inducible (iMLS), constitutive (cMLS), and efflux pump (M) resistance phenotypes. The prevalence was statistically higher (p < 0.001) in strains belonging to iMLS (84%) and cMLS (67%) phenotypes as compared to the M phenotype (15%). Interestingly, the prevalence of the prtF1 gene was significantly lower (p = 0.04) in strains belonging to M resistance phenotype as compared to erythromycin-susceptible strains (28%). Failed bacterial eradication was demonstrated in 124 patients. The prtF1 positivity rate remained unchanged in strains isolated before and after therapy in patients treated with macrolides (9/54). On the other hand, the positivity rate for the prtF1 gene was significantly higher (p = 0.015) in strains isolated after therapy with beta-lactams (21/70) as compared to baseline isolates (6/70), indicating a differential selection imposed on the organism by these agents. Finally, a high overall eradication rate (88%) of prtF1-positive isolates, belonging to both the erythromycin-susceptible and -resistant phenotypes, was demonstrated following macrolide treatment.

[1]  Kunihiko Kobayashi,et al.  Association of the prtF1 Gene (Encoding Fibronectin-Binding Protein F1) and the sic Gene (Encoding the Streptococcal Inhibitor of Complement) with emm Types of Group A Streptococci Isolated from Japanese Children with Pharyngitis , 2002, Journal of Clinical Microbiology.

[2]  E. Giovanetti,et al.  Association between erythromycin resistance and ability to enter human respiratory cells in group A streptococci , 2001, The Lancet.

[3]  B. Kreikemeyer,et al.  Persistence of group A streptococci in eukaryotic cells—a safe place? , 2001, The Lancet.

[4]  G. Rondini,et al.  Bacteriological and clinical efficacy of various antibiotics used in the treatment of streptococcal pharyngitis in Italy. An epidemiological study , 2001, International Journal of Antimicrobial Agents.

[5]  M. Rohde,et al.  The role played by the group A streptococcal negative regulator Nra on bacterial interactions with epithelial cells , 2001, Molecular microbiology.

[6]  F. Allerberger,et al.  Characterization of consecutive Streptococcus pyogenes isolates from patients with pharyngitis and bacteriological treatment failure: special reference to prtF1 and sic / drs. , 2001, The Journal of infectious diseases.

[7]  B. Kreikemeyer,et al.  Group A Streptococcal rofA Gene Is Involved in the Control of Several Virulence Genes and Eukaryotic Cell Attachment and Internalization , 2001, Infection and Immunity.

[8]  A. Barzilai,et al.  Prevalence of internalisation-associated gene, prtF1, among persisting group-A streptococcus strains isolated from asymptomatic carriers , 1998, The Lancet.

[9]  G. Cornaglia,et al.  Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. The Italian Surveillance Group for Antimicrobial Resistance. , 1996, Emerging infectious diseases.

[10]  P. Huovinen,et al.  Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. , 1993, The Journal of antimicrobial chemotherapy.

[11]  T. Klaukka,et al.  Resistance to erythromycin in group A streptococci. , 1992, The New England journal of medicine.

[12]  G. Phillips,et al.  Erythromycin-resistant Streptococcus pyogenes. , 1990, The Journal of antimicrobial chemotherapy.

[13]  P. Huovinen,et al.  ERYTHROMYCIN RESISTANCE IN GROUP A STREPTOCOCCI , 1989, The Lancet.

[14]  H. Dillon.  Streptococcal pharyngitis in the 1980s , 1987, The Pediatric infectious disease journal.

[15]  A. Komaroff,et al.  Serologic evidence of chlamydial and mycoplasmal pharyngitis in adults. , 1983, Science.

[16]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[17]  H. Sutton.  AN EPIDEMIOLOGICAL STUDY , 1937 .

[18]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[19]  C. Schalén,et al.  Protein F, a Fibronectin-binding Protein of Streptococcus Pyogenes, Also Binds Human Fibrinogen: Isolation of the Protein and Mapping of the Binding Region , 2022 .

[20]  G. Rossolini,et al.  Susceptibility of macrolide and beta-lactam antibiotics of Streptococcus pyogenes strains isolated over a four-year period in central Italy. , 1996, Journal of chemotherapy.

[21]  J. Duval.  Evolution and epidemiology of MLS resistance. , 1985, The Journal of antimicrobial chemotherapy.